| 张 巍,刘春梓,戚汝平,赵 云,杨 荣,杨 襄.数字减影血管造影引导下肝动脉化疗栓塞对肝癌患者肝功能、细胞免疫功能及肿瘤标志物的影响[J].现代生物医学进展英文版,2023,(5):887-891. |
| 数字减影血管造影引导下肝动脉化疗栓塞对肝癌患者肝功能、细胞免疫功能及肿瘤标志物的影响 |
| Effects of Digital Subtraction Angiography-Guided Transcatherter Arteril Chemoembolization on Liver Function, Cellular Immune Function and Tumor Markers in Patients with Liver Cancer |
| Received:June 28, 2022 Revised:July 24, 2022 |
| DOI：10.13241/j.cnki.pmb.2023.05.017 |
| 中文关键词: 数字减影血管造影 肝动脉化疗栓塞 肝癌 肝功能 细胞免疫功能 肿瘤标志物 |
| 英文关键词: Digital subtraction angiography Transcatherter arteril chemoembolization Liver cancer Liver function Cellular immune function Tumor markers |
| 基金项目:北京市科技计划项目（Z161100004017316） |
|
| Hits: 784 |
| Download times: 456 |
| 中文摘要: |
| 摘要 目的：探讨数字减影血管造影（DSA）引导下肝动脉化疗栓塞（TACE）对肝癌患者肝功能、细胞免疫功能及肿瘤标志物的影响。方法：随机选取2021年1月～2022年1月来我院就诊的行DSA引导下TACE化疗的肝癌患者50例为研究组，另随机选取同期行常规治疗的肝癌患者50例为对照组，对比两组临床总有效率、肝功能、细胞免疫功能及肿瘤标志物和不良反应情况。结果：研究组的临床总有效率为56.00%（28/50）高于对照组的34.00%（17/50），差异有统计学意义（P<0.05）。两组治疗结束后谷草转氨酶（AST）和谷丙转氨酶（ALT）升高，但研究组低于对照组（P<0.05）。两组治疗结束后CD8+升高，但研究组低于对照组（P<0.05）；CD4+、CD4+/CD8+、CD3+均下降，但研究组高于对照组（P<0.05）。两组治疗结束后甲胎蛋白（AFP）、糖链抗原（CA）242、CA724、磷脂酰肌醇蛋白聚糖-3（GPC3）下降，且研究组低于对照组（P<0.05）。对照组（30.00%）、研究组（24.00%）的不良反应发生率组间对比无差异（P>0.05）。结论：DSA引导下TACE化疗治疗肝癌患者，疗效可靠，可有效阻止疾病进展，同时减轻化疗所致的肝损伤和细胞免疫功能损伤。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of digital subtraction angiography (DSA)-guided transcatherter arteril chemoembolization (TACE) on liver function, cellular immune function and tumor markers in patients with liver cancer. Methods: 50 cases of liver cancer patients who underwent DSA-guided TACE chemotherapy in our hospital from January 2021 to January 2022 were randomly selected as the study group, and 50 liver cancer patients who underwent conventional chemotherapy in the same period were randomly selected as the control group. The total clinical effective rate, liver function, cellular immune function and tumor markers changes of the two groups were compared, and the adverse reactions of the two groups during treatment were recorded. Results: The total effective rate of the study group was 56.00%(28/50), higher than 34.00%(17/50) of the control group, and the difference was statistically significant(P<0.05). After treatment, aspartate aminotransferase(AST) and alanine aminotransferase(ALT) in the two groups increased, but the study group was lower than the control group(P<0.05). After treatment, CD8+ in the two groups increased, but the study group was lower than the control group(P<0.05), CD3+, CD4+, CD4+/CD8+ in the two groups after treatment decreased, but the study group was higher than the control group (P<0.05). After treatment, alpha-fetoprotein (AFP), glycan antigen (CA) 242, CA724 and phosphatidylinositol proteoglycan-3 (GPC3) in the two groups decreased, and the study group was lower than the control group(P<0.05). There was no difference in the incidence of adverse reactions between the control group(30.00%) and the study group (24.00%)(P>0.05). Conclusion: DSA-guided TACE chemotherapy has reliable efficacy in the treatment of patients with liver cancer, which can effectively prevent the progression of the disease, and alleviate the liver injury and cellular immune function injury caused by chemotherapy. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
